Valuation : Chimerix, Inc.

Market Cap 801M 690M 654M 592M 1.11B 76.53B 1.12B 7.76B 2.98B 38.94B 3.01B 2.94B 123B P/E 2023
-1.03x
P/E 2024 -3.52x
Enterprise Value 671M 578M 547M 496M 930M 64.07B 935M 6.5B 2.5B 32.59B 2.52B 2.46B 103B EV / Sales 2023
-295x
EV / Sales 2024 861x
Free-Float
89.52%
Yield 2023 *
-
Yield 2024 -
3 years 0.75
Extreme 0.75
8.55
5 years 0.75
Extreme 0.75
8.55
10 years 0.75
Extreme 0.75
11.57
Date Insider Type Main position Quantity % Market Cap. Importance
4/21/25 Issuer sale

Chief Financial Officer

1,015,869 1.1295%
4/21/25 Issuer sale

Chairman

393,055 0.4370%
4/21/25 Issuer sale

Director

631,523 0.7022%
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-.--%-.--%+679.91% 801M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.28%-2.65%+27.58%+290.71% 27.12B
Weighted average by Cap. -0.56%-2.82%+31.16%+172.16%

Financials

2023 2024
Net sales 324K 279K 264K 240K 449K 30.95M 452K 3.14M 1.21M 15.75M 1.22M 1.19M 49.76M 212K 183K 173K 157K 294K 20.25M 296K 2.05M 790K 10.3M 796K 779K 32.56M
Net income -82.1M -70.73M -66.97M -60.71M -114M -7.84B -114M -795M -306M -3.99B -308M -302M -12.61B -88.39M -76.15M -72.11M -65.36M -123M -8.44B -123M -856M -329M -4.3B -332M -325M -13.57B
Net Debt -181M -156M -148M -134M -251M -17.29B -252M -1.75B -674M -8.8B -680M -665M -27.8B -130M -112M -106M -96.47M -181M -12.46B -182M -1.26B -486M -6.34B -490M -479M -20.04B
Logo Chimerix, Inc.
Chimerix, Inc. is a biopharmaceutical company. The Company’s advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. It is conducting phase I dose escalation studies of ONC206 to evaluate safety and PK data. The second-generation imipridone (ONC206) is in dose-escalating clinical trials for adult and pediatric patients with primary central nervous system tumors. Its other product candidates include ONC212 and CMX521. ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. CMX521 is a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides. This library includes approximately 3,500 nucleoside analog compounds. It is a wholly owned subsidiary of Jazz Pharmaceuticals plc.
Employees
79
  1. Stock Market
  2. Stocks
  3. CMRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!